Video

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Tycel Phillips, MD, MPH, associate clinical professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the implications of the FDA approval of pirtobrutinib (Jaypirca) in patients with relapsed/refractory mantle cell lymphoma (MCL).

In January 2023, the regulatory agency granted accelerated approval to pirtobrutinib for the treatment of adult patients with relapsed or refractory MCL following at least 2 lines of systemic therapy, including a BTK inhibitor, based on data from a subset of patients enrolled to the open-label, single-arm phase 1/2 BRUIN trial (NCT03740529).

Findings showed that patients treated with pirtobrutinib at a daily dose of 200 mg (n = 120) experienced an overall response rate of 50% (95% CI, 41%-59%), including a complete response rate of 13% and a partial response rate of 38%. Additionally, the median time to response was 1.8 months (range, 0.8-4.2) and the median duration of response (DOR) was 8.3 months (95% CI, 5.7–not evaluable). The estimated 6-month DOR rate was 65.3% (95% CI, 49.8%-77.1%).

The approval has provided another treatment option for patients with relapsed/refractory MCL who have progressed following treatment with a covalent BTK inhibitor, Phillips says. However, long-term data on pirtobrutinib still need to be gathered and analyzed, especially as the agent more widely enters clinical practice, he adds. The expanded use will provide real-world data on how the drug affecting patients who are refractory to the covalent BTK inhibitors, Phillips explains.

In the short term, pirtobrutinib could also serve as a bridge to more definitive treatments, such as CAR T-cell therapy with brexucabtagene autoleucel (Tecartus; formerly KTE-X19). If the patients have a good response, allogeneic stem cell transplant could also be an option, Phillips continues. With limited options currently available for patients who progress on a covalent BTK inhibitor, pirtobrutinib serves as a potential treatment for patients who may not be able to access CAR T-cell therapy, Phillips concludes.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD